TP53 and ovarian carcinoma: This result means a worse survival for older than for younger patients treated with PC/PAC, as it was shown in our previous multivariate analyses on the PC/PAC group only [20,31]; TP treated patients seem to have a similar survival rate in the both age groups [[43], Ziolkowska-Seta et al: TP53, BCL-2 and BAX expressions as predictors of ovarian cancer response to taxane-platinum therapy, submitted].